Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Angiotensin receptor neprilysin inhibitors (ARNi), beyond blocking angiotensin II signaling, augment natriuretic peptides by inhibiting their breakdown by neprilysin. The myocardial effects of ARNi have been little studied until recently. We hypothesized that LCZ696 attenuates left ventricular (LV) remodeling after experimental myocardial infarction (MI), and that this may be contributed to by inhibition of hypertrophy and fibrosis in cardiac cells.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Circ Heart Fail

Title: Circulation. Heart failure

ISSN (Electronic): 1941-3297

ISSN (Print): 1941-3289

Publication date (Electronic): Jan 2015

Volume: 8

Issue: 1

Affiliations

[1 ] From the Department of Epidemiology and Preventive Medicine, Monash Center of Cardiovascular Research and Education in Therapeutics, Monash University, Alfred Hospital, Melbourne, Australia (T.G.v.L., B.H.W., A.R.K., L.H., H.K.); Department of Cardiology B, Oslo University Hospital Ullevål, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (T.G.v.L., D.A.); Department of Medicine, University of Melbourne, St Vincent's Hospital, Fitzroy, Australia (A.R.K.); Development Franchise-Critical Care, Novartis Pharma, East Hanover, NJ (R.W., P.J.); and Oncology and Drug Safety & Epidemiology, Novartis Pharma, Basel, Switzerland (P.J.).

[2 ] From the Department of Epidemiology and Preventive Medicine, Monash Center of Cardiovascular Research and Education in Therapeutics, Monash University, Alfred Hospital, Melbourne, Australia (T.G.v.L., B.H.W., A.R.K., L.H., H.K.); Department of Cardiology B, Oslo University Hospital Ullevål, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (T.G.v.L., D.A.); Department of Medicine, University of Melbourne, St Vincent's Hospital, Fitzroy, Australia (A.R.K.); Development Franchise-Critical Care, Novartis Pharma, East Hanover, NJ (R.W., P.J.); and Oncology and Drug Safety & Epidemiology, Novartis Pharma, Basel, Switzerland (P.J.). henry.krum@med.monash.edu.au.

Article

Publisher Item ID: CIRCHEARTFAILURE.114.001785

DOI: 10.1161/CIRCHEARTFAILURE.114.001785

PubMed ID: 25362207

SO-VID: 6c067447-cce8-48ea-aa58-c0ed98351252

History

Keywords: angiotensins,brain natriuretic peptide,cardiac hypertrophy,left ventricular remodeling,myocardial infarction

Data availability:

Keywords: angiotensins, brain natriuretic peptide, cardiac hypertrophy, left ventricular remodeling, myocardial infarction

Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.

Read this article at

Abstract

Related collections

Karger: Cardiovascular System

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 122

Cited by 118